Method and apparatus for dynamically monitoring multiple in vivo tissue chromophores

• US 7,248,909 B2
• Filed: 04/12/2005
• Issued: 07/24/2007
• Est. Priority Date: 04/13/2004
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: Brenner, Matthew, Tromberg, Bruce J., Cerussi, Albert E., Lee, Jangwoen
• Primary Examiner(s): Winakur; Eric
• Assistant Examiner(s): BERHANU, ETSUB D
• Application Number:
  US11/103,963
• Publication Number:
  US 20050228246A1
• Time in Patent Office: 833 Days
• Field of Search: 600/322, 600/323, 600/328, 600/326
• US Class Current: 600/322
• CPC Class Codes: A61B 5/14551 for measuring blood gases
• CPC Class Codes: A61B 5/14552 Details of sensors specially adapted therefor
• CPC Class Codes: A61B 5/412 Detecting or monitoring sepsis
• CPC Class Codes: G01N 21/31 Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry G01N21/72 takes precedence
• CPC Class Codes: G01N 21/359 using near infrared light
• CPC Class Codes: G01N 21/49 within a body or fluid
• CPC Class Codes: G01N 2201/08 Optical fibres; light guides

Abstract

A device and method utilizes a broadband diffuse optical spectroscopy (DOS) system to dynamically calculate the concentrations of multiple chromophores in vivo using a non-invasive probe. The device and method permit dynamic monitoring of multiple in vivo tissue chromophores non-invasively with sensitivities necessary for effective therapeutic monitoring. The device includes a probe containing first and second source optical fibers as well as first and second detector optical fibers. The probe is placed adjacent to a sample of interest and detects reflected light which is passed to a proximally located detector and spectrometer. The concentrations of multiple chromophores are determined in real time. In a preferred embodiment, the multiple tissue chromophores include at least two of methemoglobin (MetHb), deoxyhemoglobin (Hb-R), oxyhemoglobin (Hb-O₂), water (H₂O), and methylene blue (MB). The device and method can be used quantify and monitor methemoglobin formation in subjects suffering from methemoglobinemia.

Claims

1. A method of monitoring methemoglobinemia in a subject comprising the steps of:

providing a broadband diffuse optical spectroscopy device, the device having a first light source emitting light at a plurality of wavelengths and second light source comprising a broadband light source, first and second source optical fibers optically coupled, respectively, to the first and second light sources, first and second detector optical fibers optically coupled, respectively, to a detector and a spectrometer, the broadband diffuse optical spectroscopy device including a probe that is configured for placement adjacent to the subject'"'"'s skin;

radiating the subject with light from the first light source;

detecting intensity-modulated diffuse reflectance signals using the detector;

determining absorption and reduced scattering coefficients at each wavelength of the first light source;

radiating the subject with radiation from the second light source;

acquiring broadband reflectance measurements using the spectrometer;

determining absolute reflectance spectra based on the broadband reflectance measurements and the absorption and reduced scattering coefficients;

calculating μ

_a spectra from the absolute reflectance spectra; and

determining the concentration of methemoglobin, deoxyhemoglobin, and oxyhemoglobin, based on wavelength-dependent extinction coefficient spectra;

calculating a percentage of methemoglobin based on the formula [MetHb]/([Hb-O₂]+[Hb-R]+[MetHb]); and

displaying the percentage of methemoglobin on a computer display connected to the broadband diffuse optical spectroscopy device.

2. The method of claim 1, wherein at least one of the percentage and concentration methemoglobin is displayed on a display in real time.

3. The method of claim 1, wherein the broadband diffuse optical spectroscopy device is sensitive to 30 nM changes in MetHb levels.

4. The method of claim 1, further comprising the step of administering methylene blue to the subject and determining the concentration of methylene blue based on wavelength-dependent extinction coefficient spectra obtained from the broadband diffuse optical spectroscopy device and wherein the broadband diffuse optical spectroscopy device is sensitive to 10 nM changes in methylene blue levels.

5. The method of claim 4, further comprising displaying the concentration of deoxyhemoglobin, oxyhemoglobin, and methylene blue on the display.

6. A method of monitoring methemoglobinemia in a subject comprising the steps of:

providing a broadband diffuse optical spectroscopy device, the device having a first light source emitting light at a plurality of wavelengths and second light source comprising a broadband light source, a detector, and a spectrometer, the broadband diffuse optical spectroscopy device including a probe that is configured for placement adjacent to the subject'"'"'s skin;

radiating the subject with light from the first and second light sources;

determining the concentration of methemoglobin, deoxyhemoglobin, and oxyhemoglobin based on wavelength-dependent extinction coefficient spectra obtained from the broadband diffuse optical spectroscopy device;

calculating a percentage of methemoglobin based on the formula [MetHb]/([Hb-O₂]+[Hb-R]+[MetHb]); and

displaying at least one of the concentration and percentage of methemoglobin on a computer display operatively coupled to the broadband diffuse optical spectroscopy device.

7. The method of claim 6, further comprising the step of administering methylene blue to the subject and determining the concentration of methylene blue based on wavelength-dependent extinction coefficient spectra obtained from the broadband diffuse optical spectroscopy device.

8. The method of claim 6, wherein the at least one of concentration and percentage of methemoglobin is displayed on the display in real time.

9. The method of claim 6, wherein the broadband diffuse optical spectroscopy device is sensitive to 30 nM changes in MetHb levels.

10. The method of claim 7, wherein the broadband diffuse optical spectroscopy device is sensitive to 10 nM changes in methylene blue levels.

11. The method of claim 7, wherein the concentration of deoxyhemoglobin, oxyhemoglobin, and methylene blue are displayed on the display in real time.

12. A method of treating methemoglobinemia in a subject comprising the steps of:

providing a broadband diffuse optical spectroscopy device, the device having a first light source emitting light at a plurality of wavelengths and second light source comprising a broadband light source, a detector, and a spectrometer, the broadband diffuses optical spectroscopy device including a probe that is configured for placement adjacent to the subject'"'"'s skin;

administering methylene blue to the subject;

radiating the subject with light from the first and second light sources;

determining the concentration of methemoglobin, deoxyhemoglobin, oxyhemoglobin and methylene blue based on wavelength-dependent extinction coefficient spectra obtained from the broadband diffuse optical spectroscopy device;

calculating a percentage of methemoglobin based on the formula [MetHb]/([Hb-O₂]+[Hb-R]+[MetHb]); and

adjusting the administration of methylene based at least in part on the calculated percentage of methemoglobin.

13. The method of claim 12, wherein the percentage of methemoglobin is displayed on a display.

14. The method of claim 13, wherein the concentration of the methemoglobin is displayed on the display in real time.

15. The method of claim 12, wherein the broadband diffuse optical spectroscopy device is sensitive to 30 nM changes in MetHb levels.

16. The method of claim 12, wherein the broadband diffuse optical spectroscopy device is sensitive to 10 nM changes in methylene blue levels.

17. The method of claim 13, further comprising displaying the concentration of deoxyhemoglobin, oxyhemoglobin, and methylene blue on the display.